{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:06:49Z","timestamp":1793232409363,"version":"4.5.0"},"reference-count":124,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,12]],"date-time":"2023-11-12T00:00:00Z","timestamp":1699747200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.neurot.2023.11.001","type":"journal-article","created":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T10:34:53Z","timestamp":1702982093000},"page":"e00304","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["A clinical approach to diagnosis and management of mitochondrial myopathies"],"prefix":"10.1016","volume":"21","author":[{"given":"Hui-Lin","family":"Chin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poh San","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey Kiat Hong","family":"Tay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurot.2023.11.001_bib1","series-title":"Diagnosis and management of mitochondrial disorders","year":"2019"},{"issue":"6","key":"10.1016\/j.neurot.2023.11.001_bib2","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/joim.13054","article-title":"Mitochondrial disease in children","volume":"287","author":"Rahman","year":"2020","journal-title":"J\u00a0Intern Med"},{"issue":"12","key":"10.1016\/j.neurot.2023.11.001_bib3","first-page":"1126","volume":"27","author":"Mancuso","year":"2017","journal-title":"Inter Workshop: Neuromus Disorders"},{"key":"10.1016\/j.neurot.2023.11.001_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2020.108689","article-title":"Clinical features of mtDNA-related syndromes in adulthood","volume":"697","author":"Montano","year":"2021","journal-title":"Archiv Biochem Biophy"},{"issue":"1","key":"10.1016\/j.neurot.2023.11.001_bib5","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3390\/ijms24010124","article-title":"Remarks on Mitochondrial Myopathies","volume":"24","author":"Bottoni","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.neurot.2023.11.001_bib6","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.cell.2020.02.051","article-title":"Mitochondrial Diseases: Hope for the Future","volume":"181","author":"Russell","year":"2020","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.neurot.2023.11.001_bib7","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1055\/s-2001-17372","article-title":"Infantile presentation of the mtDNA A3243G tRNA(Leu (UUR)) mutation","volume":"32","author":"Okhuijsen-Kroes","year":"2001","journal-title":"Neuropediatrics"},{"issue":"5","key":"10.1016\/j.neurot.2023.11.001_bib8","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.nmd.2017.02.005","article-title":"Lifetime exercise intolerance with lactic acidosis as key manifestation of novel compound heterozygous ACAD9 mutations causing complex I deficiency","volume":"27","author":"Schrank","year":"2017","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.neurot.2023.11.001_bib9","series-title":"GeneReviews\u00ae [Internet]","article-title":"TK2-Related Mitochondrial DNA Maintenance Defect, Myopathic Form","author":"Wang","year":"1993"},{"key":"10.1016\/j.neurot.2023.11.001_bib10","series-title":"GeneReviews\u00ae [Internet]","article-title":"RRM2B Mitochondrial DNA Maintenance Defects","author":"Lim","year":"1993"},{"issue":"10","key":"10.1016\/j.neurot.2023.11.001_bib11","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ejmg.2017.07.010","article-title":"Homozygous c.359del variant in MGME1 is associated with early onset cerebellar ataxia","volume":"60","author":"Hebbar","year":"2017","journal-title":"Eur J Med Genet"},{"issue":"1","key":"10.1016\/j.neurot.2023.11.001_bib12","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ajhg.2010.06.001","article-title":"Mutation of the mitochondrial tyrosyl-tRNA synthetase gene, YARS2, causes myopathy, lactic acidosis, and sideroblastic anemia--MLASA syndrome","volume":"87","author":"Riley","year":"2010","journal-title":"Am J Hum Genet"},{"issue":"4","key":"10.1016\/j.neurot.2023.11.001_bib13","doi-asserted-by":"crossref","first-page":"e592","DOI":"10.1097\/MPH.0000000000001806","article-title":"A\u00a0Novel PUS1 Mutation in 2 Siblings with MLASA Syndrome: A Review of the Literature","volume":"43","author":"Oncul","year":"2021","journal-title":"J\u00a0Pediatr Hematol Oncol"},{"issue":"7","key":"10.1016\/j.neurot.2023.11.001_bib14","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/hmg\/ddy033","article-title":"A\u00a0novel mechanism causing imbalance of mitochondrial fusion and fission in human myopathies","volume":"27","author":"Bartsakoulia","year":"2018","journal-title":"Hum Mol Genet"},{"issue":"12","key":"10.1016\/j.neurot.2023.11.001_bib15","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/jmedgenet-2017-104822","article-title":"A\u00a0novel de novo dominant mutation in ISCU associated with mitochondrial myopathy","volume":"54","author":"Legati","year":"2017","journal-title":"J\u00a0Med Genet"},{"issue":"7","key":"10.1016\/j.neurot.2023.11.001_bib16","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1038\/ejhg.2013.269","article-title":"Deleterious mutation in FDX1L gene is associated with a novel mitochondrial muscle myopathy","volume":"22","author":"Spiegel","year":"2014","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.neurot.2023.11.001_bib17","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.mcp.2019.01.003","article-title":"HADHA and HADHB gene associated phenotypes - Identification of rare variants in a patient cohort by Next Generation Sequencing","volume":"44","author":"Diebold","year":"2019","journal-title":"Mol Cell Probes"},{"issue":"Pt 8","key":"10.1016\/j.neurot.2023.11.001_bib18","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1093\/brain\/awm054","article-title":"The myopathic form of coenzyme Q10 deficiency is caused by mutations in the electron-transferring-flavoprotein dehydrogenase (ETFDH) gene","volume":"130","author":"Gempel","year":"2007","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.neurot.2023.11.001_bib19","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/ajmg.c.30087","article-title":"Disorders of carnitine transport and the carnitine cycle","volume":"142C","author":"Longo","year":"2006","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"10.1016\/j.neurot.2023.11.001_bib20","series-title":"GeneReviews\u00ae [Internet]","article-title":"Very Long-Chain Acyl-Coenzyme A Dehydrogenase Deficiency","author":"Leslie","year":"1993"},{"issue":"1","key":"10.1016\/j.neurot.2023.11.001_bib21","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s10545-014-9749-9","article-title":"Genetic bases and clinical manifestations of coenzyme Q10 (CoQ 10) deficiency","volume":"38","author":"Desbats","year":"2015","journal-title":"J\u00a0Inherit Metab Dis"},{"issue":"23","key":"10.1016\/j.neurot.2023.11.001_bib22","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2020105364","article-title":"Metabolic shift underlies recovery in reversible infantile respiratory chain deficiency","volume":"39","author":"Hathazi","year":"2020","journal-title":"EMBO J"},{"issue":"4","key":"10.1016\/j.neurot.2023.11.001_bib23","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1517\/14656566.2012.657177","article-title":"Drugs and mitochondrial diseases: 40 queries and answers","volume":"13","author":"Mancuso","year":"2012","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"10.1016\/j.neurot.2023.11.001_bib24","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.cmet.2015.08.002","article-title":"Statin-Induced Myopathy Is Associated with Mitochondrial Complex III Inhibition","volume":"22","author":"Schirris","year":"2015","journal-title":"Cell Metab"},{"issue":"1","key":"10.1016\/j.neurot.2023.11.001_bib25","doi-asserted-by":"crossref","first-page":"R22","DOI":"10.1186\/cc8885","article-title":"Oxygen consumption is depressed in patients with lactic acidosis due to biguanide intoxication","volume":"14","author":"Protti","year":"2010","journal-title":"Crit Care"},{"issue":"10","key":"10.1016\/j.neurot.2023.11.001_bib26","first-page":"753","article-title":"Lactic Acidosis Induced by Linezolid Mimics Symptoms of an Acute Intracranial Bleed: A Case Report and Literature Review","volume":"8","author":"Zuccarini","year":"2016","journal-title":"J\u00a0Clin Med Res"},{"issue":"4","key":"10.1016\/j.neurot.2023.11.001_bib27","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/BF01799112","article-title":"Clinical presentation of mitochondrial disorders in childhood","volume":"19","author":"Munnich","year":"1996","journal-title":"J\u00a0Inherit Metab Dis"},{"issue":"1","key":"10.1016\/j.neurot.2023.11.001_bib28","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3390\/muscles2010007","article-title":"Diagnostic Testing in Suspected Primary Mitochondrial Myopathy","volume":"2","author":"Hinojosa","year":"2023","journal-title":"Muscles"},{"key":"10.1016\/j.neurot.2023.11.001_bib29","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2016.80","article-title":"Mitochondrial diseases","volume":"2","author":"Gorman","year":"2016","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"10.1016\/j.neurot.2023.11.001_bib30","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/j.1468-1331.2010.03012.x","article-title":"EFNS guidelines on the diagnostic approach to pauci- or asymptomatic hyperCKemia","volume":"17","author":"Kyriakides","year":"2010","journal-title":"Eur J Neurol"},{"issue":"6","key":"10.1016\/j.neurot.2023.11.001_bib31","doi-asserted-by":"crossref","first-page":"e519","DOI":"10.1212\/NXG.0000000000000519","article-title":"Primary mitochondrial myopathy: Clinical features and outcome measures in 118 cases from Italy","volume":"6","author":"Montano","year":"2020","journal-title":"Neurol Genet"},{"issue":"1","key":"10.1016\/j.neurot.2023.11.001_bib32","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ymgme.2007.11.018","article-title":"The in-depth evaluation of suspected mitochondrial disease","volume":"94","author":"Haas","year":"2008","journal-title":"Mol Genet Metab"},{"issue":"8","key":"10.1016\/j.neurot.2023.11.001_bib33","first-page":"80","article-title":"Use of FGF-21 as a Biomarker of Mitochondrial Disease in Clinical Practice","volume":"6","author":"Morovat","year":"2017","journal-title":"J\u00a0Clin Med"},{"issue":"7","key":"10.1016\/j.neurot.2023.11.001_bib34","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41576-018-0022-1","article-title":"First-line genomic diagnosis of mitochondrial disorders","volume":"19","author":"Raymond","year":"2018","journal-title":"Nat Rev Genet"},{"issue":"9","key":"10.1016\/j.neurot.2023.11.001_bib35","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.tig.2020.06.009","article-title":"Mitochondrial Diseases: A Diagnostic Revolution","volume":"36","author":"Schon","year":"2020","journal-title":"Trends Genet"},{"issue":"3","key":"10.1016\/j.neurot.2023.11.001_bib36","first-page":"632","article-title":"Molecular Genetics Overview of Primary Mitochondrial Myopathies","volume":"11","author":"Arena","year":"2022","journal-title":"J\u00a0Clin Med"},{"issue":"138","key":"10.1016\/j.neurot.2023.11.001_bib37","doi-asserted-by":"crossref","first-page":"138ra78","DOI":"10.1126\/scitranslmed.3003544","article-title":"Exome sequencing can improve diagnosis and alter patient management","volume":"4","author":"Dixon-Salazar","year":"2012","journal-title":"Sci Transl Med"},{"issue":"12","key":"10.1016\/j.neurot.2023.11.001_bib38","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1002\/humu.24107","article-title":"Specifications of the ACMG\/AMP standards and guidelines for mitochondrial DNA variant interpretation","volume":"41","author":"McCormick","year":"2020","journal-title":"Hum Mutat"},{"key":"10.1016\/j.neurot.2023.11.001_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2022.692257","article-title":"Benchmarking the Effectiveness and Accuracy of Multiple Mitochondrial DNA Variant Callers: Practical Implications for Clinical Application","volume":"13","author":"Ip","year":"2022","journal-title":"Front Genet"},{"issue":"1","key":"10.1016\/j.neurot.2023.11.001_bib40","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/jmedgenet-2019-106800","article-title":"Six-year prospective follow-up study in 151 carriers of the mitochondrial DNA 3243 A>G variant","volume":"58","author":"de Laat","year":"2021","journal-title":"J\u00a0Med Genet"},{"issue":"2","key":"10.1016\/j.neurot.2023.11.001_bib41","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3390\/genes11020212","article-title":"Heteroplasmy and Copy Number in the Common m.3243A>G Mutation-A Post-Mortem Genotype-Phenotype Analysis","volume":"11","author":"Scholle","year":"2020","journal-title":"Genes (Basel)"},{"issue":"6","key":"10.1016\/j.neurot.2023.11.001_bib42","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201708262","article-title":"mtDNA heteroplasmy level and copy number indicate disease burden in m.3243A>G mitochondrial disease","volume":"10","author":"Grady","year":"2018","journal-title":"EMBO Mol Med"},{"issue":"3","key":"10.1016\/j.neurot.2023.11.001_bib43","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/acn3.532","article-title":"Phenotypic heterogeneity in m.3243A>G mitochondrial disease: The role of nuclear factors","volume":"5","author":"Pickett","year":"2018","journal-title":"Ann Clin Transl Neurol"},{"issue":"2","key":"10.1016\/j.neurot.2023.11.001_bib44","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/ene.13176","article-title":"Prediction of long-term prognosis by heteroplasmy levels of the m.3243A>G mutation in patients with the mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes syndrome","volume":"24","author":"Fayssoil","year":"2017","journal-title":"Eur J Neurol"},{"issue":"20","key":"10.1016\/j.neurot.2023.11.001_bib45","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222011080","article-title":"Multi-Omics Approach to Mitochondrial DNA Damage in Human Muscle Fibers","volume":"22","author":"Elstner","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.neurot.2023.11.001_bib46","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41582-021-00455-2","article-title":"Applying genomic and transcriptomic advances to mitochondrial medicine","volume":"17","author":"Macken","year":"2021","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.neurot.2023.11.001_bib47","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2023.1089956","article-title":"Nanopore long-read next-generation sequencing for detection of mitochondrial DNA large-scale deletions","volume":"14","author":"Frascarelli","year":"2023","journal-title":"Front Genet"},{"key":"10.1016\/j.neurot.2023.11.001_bib48","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.mito.2022.06.003","article-title":"Long read mitochondrial genome sequencing using Cas9-guided adaptor ligation","volume":"65","author":"Vandiver","year":"2022","journal-title":"Mitochondrion"},{"issue":"6","key":"10.1016\/j.neurot.2023.11.001_bib49","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1002\/acn3.51787","article-title":"A\u00a0different pattern of clinical, muscle pathology and brain MRI findings in MELAS with mt-ND variants","volume":"10","author":"Wang","year":"2023","journal-title":"Ann Clin Transl Neurol"},{"issue":"12","key":"10.1016\/j.neurot.2023.11.001_bib50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1009242","article-title":"Accurate mapping of mitochondrial DNA deletions and duplications using deep sequencing","volume":"16","author":"Basu","year":"2020","journal-title":"PLoS Genet"},{"issue":"10","key":"10.1016\/j.neurot.2023.11.001_bib51","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.nmd.2021.08.005","article-title":"Primary mitochondrial myopathies in childhood","volume":"31","author":"Olimpio","year":"2021","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.neurot.2023.11.001_bib52","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/978-1-61779-504-6_6","article-title":"Mitochondrial respiratory chain: biochemical analysis and criterion for deficiency in diagnosis","volume":"837","author":"Grazina","year":"2012","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.neurot.2023.11.001_bib53","doi-asserted-by":"crossref","DOI":"10.1038\/srep15037","article-title":"A\u00a0novel immunofluorescent assay to investigate oxidative phosphorylation deficiency in mitochondrial myopathy: understanding mechanisms and improving diagnosis","volume":"5","author":"Rocha","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.neurot.2023.11.001_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.ensci.2021.100360","article-title":"Lactate peak in muscle disclosed by magnetic resonance spectroscopy in a patient with CPEO-plus syndrome","volume":"24","author":"Fan","year":"2021","journal-title":"eNeurologicalSci"},{"issue":"12","key":"10.1016\/j.neurot.2023.11.001_bib55","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.3390\/genes11121522","article-title":"Fourier-Transform Infrared Spectroscopy of Skeletal Muscle Tissue: Expanding Biomarkers in Primary Mitochondrial Myopathies","volume":"11","author":"Gervasoni","year":"2020","journal-title":"Genes (Basel)"},{"issue":"5\u20136","key":"10.1016\/j.neurot.2023.11.001_bib56","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.mito.2008.05.003","article-title":"Neuroimaging of mitochondrial disease","volume":"8","author":"Saneto","year":"2008","journal-title":"Mitochondrion"},{"issue":"Pt 5","key":"10.1016\/j.neurot.2023.11.001_bib57","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1093\/brain\/111.5.1009","article-title":"The cerebral metabolism of glucose and oxygen measured with positron tomography in patients with mitochondrial diseases","volume":"111","author":"Frackowiak","year":"1988","journal-title":"Brain"},{"issue":"12","key":"10.1016\/j.neurot.2023.11.001_bib58","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1212\/01.wnl.0000219759.72195.41","article-title":"Mitochondrial disease in adults: a scale to monitor progression and treatment","volume":"66","author":"Schaefer","year":"2006","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.neurot.2023.11.001_bib59","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s10545-016-9948-7","article-title":"International Paediatric Mitochondrial Disease Scale","volume":"39","author":"Koene","year":"2016","journal-title":"J\u00a0Inherit Metab Dis"},{"issue":"1","key":"10.1016\/j.neurot.2023.11.001_bib60","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s41687-022-00534-y","article-title":"Psychometric performance of the Primary Mitochondrial Myopathy Symptom Assessment (PMMSA) in a randomized, double-blind, placebo-controlled crossover study in subjects with mitochondrial disease","volume":"6","author":"Gwaltney","year":"2022","journal-title":"J\u00a0Patient Rep Outcomes"},{"issue":"8","key":"10.1016\/j.neurot.2023.11.001_bib61","first-page":"1796","article-title":"Exercise Testing, Physical Training and Fatigue in Patients with Mitochondrial Myopathy Related to mtDNA Mutations","volume":"10","author":"Jeppesen","year":"2021","journal-title":"J\u00a0Clin Med"},{"issue":"11","key":"10.1016\/j.neurot.2023.11.001_bib62","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1093\/brain\/aww222","article-title":"The metabolomic signature of Leber\u2019s hereditary optic neuropathy reveals endoplasmic reticulum stress","volume":"139","author":"Chao de la Barca","year":"2016","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.neurot.2023.11.001_bib63","first-page":"16","article-title":"Biomarkers for Detecting Mitochondrial Disorders","volume":"7","author":"Finsterer","year":"2018","journal-title":"J\u00a0Clin Med"},{"issue":"6","key":"10.1016\/j.neurot.2023.11.001_bib64","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/MOP.0000000000000954","article-title":"Mitochondrial medicine therapies: rationale, evidence, and dosing guidelines","volume":"32","author":"Barcelos","year":"2020","journal-title":"Curr Opin Pediatr"},{"issue":"12","key":"10.1016\/j.neurot.2023.11.001_bib65","first-page":"1380","article-title":"Patient care standards for primary mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society","volume":"19","author":"Parikh","year":"2017","journal-title":"Genetics in Medicine"},{"issue":"4","key":"10.1016\/j.neurot.2023.11.001_bib66","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/jimd.12196","article-title":"Safety of drug use in patients with a primary mitochondrial disease: An international Delphi-based consensus","volume":"43","author":"De Vries","year":"2020","journal-title":"J\u00a0Inherit Metab Dis"},{"issue":"5","key":"10.1016\/j.neurot.2023.11.001_bib67","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jacl.2020.07.007","article-title":"Successful treatment of a patient with mitochondrial myopathy with alirocumab","volume":"14","author":"Cicero","year":"2020","journal-title":"J\u00a0Clin Lipidol"},{"issue":"23","key":"10.1016\/j.neurot.2023.11.001_bib68","doi-asserted-by":"crossref","first-page":"e2318","DOI":"10.1212\/WNL.0000000000200299","article-title":"l-Arginine in Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like Episodes: A Systematic Review","volume":"98","author":"Stefanetti","year":"2022","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.neurot.2023.11.001_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2023.166769","article-title":"Regulating mitochondrial metabolism by targeting pyruvate dehydrogenase with dichloroacetate, a metabolic messenger","volume":"1869","author":"Schoenmann","year":"2023","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"12","key":"10.1016\/j.neurot.2023.11.001_bib70","first-page":"2861","article-title":"Therapeutic regimen of L-arginine for MELAS: 9-year, prospective, multicenter, clinical research","volume":"265","author":"Koga","year":"2018","journal-title":"J\u00a0Neurol"},{"issue":"9","key":"10.1016\/j.neurot.2023.11.001_bib71","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1177\/0883073814538512","article-title":"Exercise as a therapeutic strategy for primary mitochondrial cytopathies","volume":"29","author":"Tarnopolsky","year":"2014","journal-title":"J\u00a0Child Neurol"},{"issue":"5","key":"10.1016\/j.neurot.2023.11.001_bib72","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1113\/JP270079","article-title":"Mitochondrial function at extreme high altitude","volume":"594","author":"Murray","year":"2016","journal-title":"J\u00a0Physiol"},{"issue":"12","key":"10.1016\/j.neurot.2023.11.001_bib73","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1111\/ene.15526","article-title":"European Neuromuscular Centre consensus statement on anaesthesia in patients with neuromuscular disorders","volume":"29","author":"van den Bersselaar","year":"2022","journal-title":"Eur J Neurol"},{"issue":"4","key":"10.1016\/j.neurot.2023.11.001_bib74","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.bja.2018.12.025","article-title":"Propofol infusion syndrome: a structured literature review and analysis of published case reports","volume":"122","author":"Hemphill","year":"2019","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.neurot.2023.11.001_bib75","article-title":"Mitochondrial Disease and Anesthesia","volume":"5","author":"Hsieh","year":"2017","journal-title":"J\u00a0Inborn Errors Metabol Screen"},{"issue":"6\u20132017","key":"10.1016\/j.neurot.2023.11.001_bib76","first-page":"S125","article-title":"Mitochondrial disorders","author":"Hoppe","year":"2017","journal-title":"Mitochondrial Disorders"},{"issue":"2","key":"10.1016\/j.neurot.2023.11.001_bib77","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s40291-020-00510-6","article-title":"Current and Emerging Clinical Treatment in Mitochondrial Disease","volume":"25","author":"Tinker","year":"2021","journal-title":"Mol Diagn Ther"},{"issue":"11","key":"10.1016\/j.neurot.2023.11.001_bib78","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1038\/ejhg.2014.35","article-title":"A\u00a0national perspective on prenatal testing for mitochondrial disease","volume":"22","author":"Nesbitt","year":"2014","journal-title":"Eur J Hum Genet"},{"issue":"4","key":"10.1016\/j.neurot.2023.11.001_bib79","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/rmb2.12230","article-title":"Mitochondrial replacement therapy and assisted reproductive technology: A paradigm shift toward treatment of genetic diseases in gametes or in early embryos","volume":"17","author":"Tachibana","year":"2018","journal-title":"Reprod Med Biol"},{"issue":"4","key":"10.1016\/j.neurot.2023.11.001_bib80","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/s41551-022-00881-7","article-title":"Reduction of mtDNA heteroplasmy in mitochondrial replacement therapy by inducing forced mitophagy","volume":"6","author":"Fan","year":"2022","journal-title":"Nat Biomed Eng"},{"issue":"3","key":"10.1016\/j.neurot.2023.11.001_bib81","first-page":"597","article-title":"Mitochondrial Replacement Therapy: In Whose Interests?","volume":"50","author":"Noohi","year":"2022","journal-title":"J\u00a0Law Med Ethics"},{"key":"10.1016\/j.neurot.2023.11.001_bib82","doi-asserted-by":"crossref","first-page":"552","DOI":"10.3389\/fneur.2018.00552","article-title":"KL1333, a Novel NAD+ Modulator, Improves Energy Metabolism and Mitochondrial Dysfunction in MELAS Fibroblasts","volume":"9","author":"Seo","year":"2018","journal-title":"Front Neurol"},{"issue":"7","key":"10.1016\/j.neurot.2023.11.001_bib83","doi-asserted-by":"crossref","first-page":"e687","DOI":"10.1212\/WNL.0000000000008861","article-title":"Safety and efficacy of omaveloxolone in patients with mitochondrial myopathy: MOTOR trial","volume":"94","author":"Madsen","year":"2020","journal-title":"Neurology"},{"issue":"17","key":"10.1016\/j.neurot.2023.11.001_bib84","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.3390\/cells11172635","article-title":"Treatment of VLCAD-Deficient Patient Fibroblasts with Peroxisome Proliferator-Activated Receptor \u03b4 Agonist Improves Cellular Bioenergetics","volume":"11","author":"D\u2019Annibale","year":"2022","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.neurot.2023.11.001_bib85","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201911589","article-title":"Metabolic effects of bezafibrate in mitochondrial disease","volume":"12","author":"Steele","year":"2020","journal-title":"EMBO Mol Med"},{"issue":"4","key":"10.1016\/j.neurot.2023.11.001_bib86","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.2337\/db14-0667","article-title":"Evidence for a direct effect of the NAD+ precursor acipimox on muscle mitochondrial function in humans","volume":"64","author":"van de Weijer","year":"2015","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.neurot.2023.11.001_bib87","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1186\/s13063-022-06544-x","article-title":"Acipimox in Mitochondrial Myopathy (AIMM): study protocol for a randomised, double-blinded, placebo-controlled, adaptive design trial of the efficacy of acipimox in adult patients with mitochondrial myopathy","volume":"23","author":"Abouhajar","year":"2022","journal-title":"Trials"},{"issue":"3","key":"10.1016\/j.neurot.2023.11.001_bib88","doi-asserted-by":"crossref","first-page":"e238","DOI":"10.1212\/WNL.0000000000207402","article-title":"Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial","volume":"101","author":"Karaa","year":"2023","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.neurot.2023.11.001_bib89","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1186\/s13023-022-02469-5","article-title":"Natural history comparison study to assess the efficacy of elamipretide in patients with Barth syndrome","volume":"17","author":"Hornby","year":"2022","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"10.1016\/j.neurot.2023.11.001_bib90","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1097\/WCO.0000000000000743","article-title":"Advances in primary mitochondrial myopathies","volume":"32","author":"de Barcelos","year":"2019","journal-title":"Curr Opin Neurol"},{"issue":"4","key":"10.1016\/j.neurot.2023.11.001_bib91","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1002\/jcsm.12559","article-title":"A\u00a0randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy","volume":"11","author":"Karaa","year":"2020","journal-title":"J\u00a0Cachexia Sarcopenia Muscle"},{"issue":"14","key":"10.1016\/j.neurot.2023.11.001_bib92","doi-asserted-by":"crossref","first-page":"e1212","DOI":"10.1212\/WNL.0000000000005255","article-title":"Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy","volume":"90","author":"Karaa","year":"2018","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.neurot.2023.11.001_bib93","first-page":"65","article-title":"Use of Elamipretide in patients assigned treatment in the compassionate use program: Case series in pediatric patients with rare orphan diseases","volume":"64","author":"Koenig","year":"2023","journal-title":"JIMD Rep"},{"issue":"2","key":"10.1016\/j.neurot.2023.11.001_bib94","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/ana.25506","article-title":"Deoxynucleoside Therapy for Thymidine Kinase 2-Deficient Myopathy","volume":"86","author":"Dom\u00ednguez-Gonz\u00e1lez","year":"2019","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.neurot.2023.11.001_bib95","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2020-000774","article-title":"Deoxynucleoside therapy for respiratory involvement in adult patients with thymidine kinase 2-deficient myopathy","volume":"7","author":"Hernandez-Voth","year":"2020","journal-title":"BMJ Open Respir Res"},{"issue":"4","key":"10.1016\/j.neurot.2023.11.001_bib96","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/ana.26185","article-title":"Synergistic Deoxynucleoside and Gene Therapies for Thymidine Kinase 2 Deficiency","volume":"90","author":"Lopez-Gomez","year":"2021","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1016\/j.neurot.2023.11.001_bib97","first-page":"457","article-title":"Safety and Efficacy of Erythrocyte Encapsulated Thymidine Phosphorylase in Mitochondrial Neurogastrointestinal Encephalomyopathy","volume":"8","author":"Levene","year":"2019","journal-title":"J\u00a0Clin Med"},{"issue":"8","key":"10.1016\/j.neurot.2023.11.001_bib98","first-page":"1096","article-title":"Erythrocyte Encapsulated Thymidine Phosphorylase for the Treatment of Patients with Mitochondrial Neurogastrointestinal Encephalomyopathy: Study Protocol for a Multi-Centre, Multiple Dose, Open Label Trial","volume":"8","author":"Bax","year":"2019","journal-title":"J\u00a0Clin Med"},{"issue":"3","key":"10.1016\/j.neurot.2023.11.001_bib99","first-page":"788","article-title":"Quantification of Plasma and Urine Thymidine and 2\u2019-Deoxyuridine by LC-MS\/MS for the Pharmacodynamic Evaluation of Erythrocyte Encapsulated Thymidine Phosphorylase in Patients with Mitochondrial Neurogastrointestinal Encephalomyopathy","volume":"9","author":"Kipper","year":"2020","journal-title":"J\u00a0Clin Med"},{"issue":"5","key":"10.1016\/j.neurot.2023.11.001_bib100","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1136\/jnnp-2018-317964","article-title":"Taurine supplementation for prevention of stroke-like episodes in MELAS: a multicentre, open-label, 52-week phase III trial","volume":"90","author":"Ohsawa","year":"2019","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"6","key":"10.1016\/j.neurot.2023.11.001_bib101","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.cmet.2020.04.008","article-title":"Niacin Cures Systemic NAD+ Deficiency and Improves Muscle Performance in Adult-Onset Mitochondrial Myopathy","volume":"31","author":"Pirinen","year":"2020","journal-title":"Cell Metab"},{"issue":"6","key":"10.1016\/j.neurot.2023.11.001_bib102","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.cmet.2020.05.013","article-title":"Of Mice and Men: NAD+ Boosting with Niacin Provides Hope for Mitochondrial Myopathy Patients","volume":"31","author":"Chini","year":"2020","journal-title":"Cell Metab"},{"issue":"2","key":"10.1016\/j.neurot.2023.11.001_bib103","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/ene.15626","article-title":"High-dose oral glutamine supplementation reduces elevated glutamate levels in cerebrospinal fluid in patients with mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes syndrome","volume":"30","author":"Guerrero-Molina","year":"2023","journal-title":"Eur J Neurol"},{"issue":"5","key":"10.1016\/j.neurot.2023.11.001_bib104","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1002\/jimd.12393","article-title":"No effect of resveratrol in patients with mitochondrial myopathy: A cross-over randomized controlled trial","volume":"44","author":"L\u00f8kken","year":"2021","journal-title":"J\u00a0Inherit Metab Dis"},{"issue":"3","key":"10.1016\/j.neurot.2023.11.001_bib105","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/jimd.12479","article-title":"No effect of resveratrol on fatty acid oxidation or exercise capacity in patients with fatty acid oxidation disorders: A randomized clinical cross-over trial","volume":"45","author":"Storgaard","year":"2022","journal-title":"J\u00a0Inherit Metab Dis"},{"key":"10.1016\/j.neurot.2023.11.001_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/j.biocel.2021.106050","article-title":"The ketogenic diet as a therapeutic intervention strategy in mitochondrial disease","volume":"138","author":"Qu","year":"2021","journal-title":"Int J Biochem Cell Biol"},{"issue":"3","key":"10.1016\/j.neurot.2023.11.001_bib107","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1152\/japplphysiol.00885.2015","article-title":"Home-based aerobic exercise training improves skeletal muscle oxidative metabolism in patients with metabolic myopathies","volume":"121","author":"Porcelli","year":"2016","journal-title":"J\u00a0Appl Physiol (1985)"},{"issue":"12","key":"10.1016\/j.neurot.2023.11.001_bib108","article-title":"Strength training and aerobic exercise training for muscle disease","volume":"12","author":"Voet","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.neurot.2023.11.001_bib109","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12868-016-0259-6","article-title":"Comparative assessment of phototherapy protocols for reduction of oxidative stress in partially transected spinal cord slices undergoing secondary degeneration","volume":"17","author":"Ashworth","year":"2016","journal-title":"BMC Neurosci"},{"issue":"97","key":"10.1016\/j.neurot.2023.11.001_bib110","article-title":"Method for the assessment of effects of a range of wavelengths and intensities of red\/near-infrared light therapy on oxidative stress in vitro","author":"Giacci","year":"2015","journal-title":"J\u00a0Vis Exp"},{"key":"10.1016\/j.neurot.2023.11.001_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuint.2019.104491","article-title":"Neuroprotective effect of anodal transcranial direct current stimulation on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity in mice through modulating mitochondrial dynamics","volume":"129","author":"Lee","year":"2019","journal-title":"Neurochem Int"},{"issue":"9","key":"10.1016\/j.neurot.2023.11.001_bib112","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.2724","article-title":"A\u00a0systematic review of randomized controlled trials on efficacy and safety of transcranial direct current stimulation in major neurodevelopmental disorders: ADHD, autism, and dyslexia","volume":"12","author":"Salehinejad","year":"2022","journal-title":"Brain Behav"},{"issue":"4","key":"10.1016\/j.neurot.2023.11.001_bib113","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1177\/1120672120952344","article-title":"Surgical management of ptosis in chronic progressive external ophthalmoplegia","volume":"31","author":"Eshaghi","year":"2021","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.neurot.2023.11.001_bib114","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkad139","article-title":"Restoration of mitochondrial function through activation of hypomodified tRNAs with pathogenic mutations associated with mitochondrial diseases","author":"Tomoda","year":"2023","journal-title":"Nucleic Acids Res"},{"issue":"10","key":"10.1016\/j.neurot.2023.11.001_bib115","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/gt.2017.53","article-title":"AAV9-based gene therapy partially ameliorates the clinical phenotype of a mouse model of Leigh syndrome","volume":"24","author":"Di Meo","year":"2017","journal-title":"Gene Ther"},{"issue":"6","key":"10.1016\/j.neurot.2023.11.001_bib116","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1093\/brain\/awaa105","article-title":"Gene replacement therapy provides benefit in an adult mouse model of Leigh syndrome","volume":"143","author":"Reynaud-Dulaurier","year":"2020","journal-title":"Brain"},{"key":"10.1016\/j.neurot.2023.11.001_bib117","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.omtm.2020.04.026","article-title":"A\u00a0Single Intravenous Injection of AAV-PHP.B-hNDUFS4 Ameliorates the Phenotype of Ndufs4 -\/- Mice","volume":"17","author":"Silva-Pinheiro","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"19","key":"10.1016\/j.neurot.2023.11.001_bib118","doi-asserted-by":"crossref","first-page":"13323","DOI":"10.1074\/jbc.M113.528968","article-title":"Modeling of antigenomic therapy of mitochondrial diseases by mitochondrially addressed RNA targeting a pathogenic point mutation in mitochondrial DNA","volume":"289","author":"Tonin","year":"2014","journal-title":"J\u00a0Biol Chem"},{"issue":"1","key":"10.1016\/j.neurot.2023.11.001_bib119","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1093\/nar\/gks965","article-title":"Mitochondrial targeting of recombinant RNAs modulates the level of a heteroplasmic mutation in human mitochondrial DNA associated with Kearns Sayre Syndrome","volume":"41","author":"Comte","year":"2013","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"10.1016\/j.neurot.2023.11.001_bib120","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1021\/acssynbio.8b00411","article-title":"Knock-In Strategy for Editing Human and Zebrafish Mitochondrial DNA Using Mito-CRISPR\/Cas9 System","volume":"8","author":"Bian","year":"2019","journal-title":"ACS Synth Biol"},{"issue":"6","key":"10.1016\/j.neurot.2023.11.001_bib121","doi-asserted-by":"crossref","DOI":"10.1016\/j.xinn.2022.100329","article-title":"Direct evidence of CRISPR-Cas9-mediated mitochondrial genome editing","volume":"3","author":"Bi","year":"2022","journal-title":"The Innovation"},{"issue":"4","key":"10.1016\/j.neurot.2023.11.001_bib122","doi-asserted-by":"crossref","DOI":"10.15252\/embr.202255678","article-title":"Modeling mitochondrial DNA diseases: from base editing to pluripotent stem-cell-derived organoids","volume":"24","author":"Tolle","year":"2023","journal-title":"EMBO Reports"},{"issue":"7817","key":"10.1016\/j.neurot.2023.11.001_bib123","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/s41586-020-2477-4","article-title":"A\u00a0bacterial cytidine deaminase toxin enables CRISPR-free mitochondrial base editing","volume":"583","author":"Mok","year":"2020","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.neurot.2023.11.001_bib124","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1038\/s41587-022-01256-8","article-title":"CRISPR-free base editors with enhanced activity and expanded targeting scope in mitochondrial and nuclear DNA","volume":"40","author":"Mok","year":"2022","journal-title":"Nat Biotechnol"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923019402?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923019402?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:15:41Z","timestamp":1761808541000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923019402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":124,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S1878747923019402"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2023.11.001","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A clinical approach to diagnosis and management of mitochondrial myopathies","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2023.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00304"}}